CD8A and cancer: Some studies show that TAM induces immune-polarizing side effects (IPSE) in cancer patients, promoting a Th2 bias and impairing therapeutic outcomes by decreasing the CD8+/Treg ratio and CD8 and Natural Killer (NK) cell activity (26, 27, 37).